To better understand how HDAC inhibitors fight against tumors at the cellular level and to explore their specific application in T-ALL, two novel HDAC inhibitors (NBU-1 and NBU-2) were designed and synthesized based on hydroxamic acid fragments. This evidence concerns the gene HDAC9 and acute lymphoblastic leukemia.